ANRO News

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

Alto Neuroscience, Inc. Class Action Notice: ANRO Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Securities Lawsuit

Shareholders that lost money on Alto Neuroscience, Inc.(ANRO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

Faruqi & Faruqi Reminds Alto Neuroscience Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 19, 2025 - ANRO

Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO

The Gross Law Firm Reminds Alto Neuroscience, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 19, 2025 - ANRO

ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm

ANRO Deadline: ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit

Alto Neuroscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ANRO

Contact The Gross Law Firm by September 19, 2025 Deadline to Join Class Action Against Alto Neuroscience, Inc.(ANRO)